2. The FDA plans to send a "Dear Doctor" letter to every physician and hospital administrator throughout the country warning of the hazards of this drug and stating, in a positive manner, its indications for use. We will seek support at all levels of the medical profession, down to the county societies, to be sure the message gets through to all prescribers.

3. All "reminder ads" for the drug will be required to carry a brief summary of the dangers of the side effects associated with chloramphenicol; that is, every ad will be required to carry at least the "box warning."

In addition to these considerations, we have consulated with a special Ad Hoc Committee which met Monday, February 26, 1968 at the FDA Headquarters. This Committee was convened specifically to consider the chloramphenicol problem, and to advise the FDA on the action we proposed to take to improve the prescribing information for this drug and to disseminate this information throughout the medical community.

The Committee's opinion was that we should communicate directly with doctors and hospital administrators on new labeling for chloramphenicol. In addition, the Committee suggested contacting various professional publications—*Medical Tribune, Medical World News, AMA News,* and the journals of every State medical society—to ask their cooperation in publicizing the proper use of the drug and the hazards associated with its use. This will be done. The Committee will shortly give us further results of its considerations concerning pediatric dosages for the drug.

Mr. Chairman, we are most anxious to implement immediately all appropriate recommendations in order to take full advantage of the wide interest created by this Committee's hearings.

I thank you for your time and attention this morning. If there are questions, I would be happy to answer them.

(Whereupon, at 1 p.m. the subcommittee was adjourned, to reconvene subject to the call of the Chair.)